SMS Pharmaceuticals Balans Gezondheid
Financiële gezondheid criteriumcontroles 4/6
SMS Pharmaceuticals heeft een totaal eigen vermogen van ₹5.6B en een totale schuld van ₹2.9B, wat de schuld-eigenvermogensverhouding op 50.6% brengt. De totale activa en totale passiva bedragen respectievelijk ₹11.3B en ₹5.7B. De EBIT SMS Pharmaceuticals is ₹955.7M waardoor de rentedekking 5 is. Het heeft contanten en kortetermijnbeleggingen van ₹90.7M.
Belangrijke informatie
50.6%
Verhouding schuld/eigen vermogen
₹2.85b
Schuld
| Rente dekkingsratio | 5x |
| Contant | ₹90.66m |
| Aandelen | ₹5.64b |
| Totaal verplichtingen | ₹5.71b |
| Totaal activa | ₹11.35b |
Recente financiële gezondheidsupdates
Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Can Manage Its Debt Responsibly
Jun 21
SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet
Jun 07We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt
Mar 22Recent updates
Risks Still Elevated At These Prices As SMS Pharmaceuticals Limited (NSE:SMSPHARMA) Shares Dive 25%
Nov 14SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Sep 07SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be Increased To ₹0.40
Aug 22Earnings Not Telling The Story For SMS Pharmaceuticals Limited (NSE:SMSPHARMA) After Shares Rise 27%
Aug 20SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Aug 08What SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 27% Share Price Gain Is Not Telling You
Jul 04Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Can Manage Its Debt Responsibly
Jun 21SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 25% Share Price Surge Not Quite Adding Up
Feb 29SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be ₹0.30
Sep 11SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 28SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet
Jun 07Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23SMS Pharmaceuticals (NSE:SMSPHARMA) Is Due To Pay A Dividend Of ₹0.30
Sep 15SMS Pharmaceuticals (NSE:SMSPHARMA) Will Pay A Dividend Of ₹0.30
Sep 01SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 18We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt
Mar 22SMS Pharmaceuticals' (NSE:SMSPHARMA) Earnings Are Of Questionable Quality
Jun 03Should You Be Adding SMS Pharmaceuticals (NSE:SMSPHARMA) To Your Watchlist Today?
Mar 08What Type Of Shareholders Make Up SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Registry?
Feb 22The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 185% And Shareholders Are Boasting About It
Feb 08SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 18
Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( ₹5.8B ) SMSPHARMA } overtreffen de korte termijn passiva ( ₹3.8B ).
Langlopende schulden: De kortetermijnactiva SMSPHARMA ( ₹5.8B ) overtreffen de langetermijnschulden ( ₹2.0B ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: De netto schuld/eigen vermogen ratio ( 49% ) SMSPHARMA wordt als hoog beschouwd.
Schuld verminderen: De schuld/eigen vermogen-ratio van SMSPHARMA is de afgelopen 5 jaar gestegen van 43.2% naar 50.6%.
Schuldendekking: De schuld van SMSPHARMA wordt goed gedekt door de operationele kasstroom ( 22.9% ).
Rentedekking: De rentebetalingen op de schuld van SMSPHARMA worden goed gedekt door EBIT ( 5 x dekking).